Arkolith/Insider Trading/HALO/Form 4

Torley Helen

PRESIDENT AND CEO, DirectorHALOZYME THERAPEUTICS, INC. (HALO) · full profile →Form 4 · filed Apr 2, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$2.6M
Net Open-Market Flow
-$2.6M
Transactions
8
6 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 2, 2026Option exercise(M)20K$12.07$241K788K
Apr 2, 2026Sell(S)16K$64.06$1.0M772K
Apr 2, 2026Sell(S)4K$64.89$273K768K
Apr 1, 2026Option exercise(M)20K$12.07$241K788K
Apr 1, 2026Sell(S)19K$65.36$1.2M769K
Apr 1, 2026Sell(S)1K$65.71$66K768K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 2, 2026Option exercise(M)20K$12.07$241K112K
Apr 1, 2026Option exercise(M)20K$12.07$241K132K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001159036-26-000046) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML